Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | GAA | P10253 | 5/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | QPCT | Q16769 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 3/20 | 0.31 |
| ▸ | CCR3 | P51677 | 1/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2290054 | 0.94 | MAPT (0.36) | MAPTGAAQPCTTHRBTP53 | |
| SCHEMBL2290413 | 0.94 | MAPT (0.36) | MAPTGAAQPCTTHRBTP53 | |
| SCHEMBL2290154 | 0.93 | MAPT (0.35) | MAPTGAAQPCTTHRBTP53 | |
| SCHEMBL2288199 | 0.92 | MAPT (0.41) | MAPTGAASYKTHRBTP53 | |
| SCHEMBL2293465 | 0.90 | TRPA1 (0.40) | MAPTGAASYKQPCTTP53 | |
| SCHEMBL2289661 | 0.89 | MAPT (0.40) | MAPTGAATHRBTP53TRPA1 | |
| SCHEMBL2290088 | 0.89 | MAPT (0.39) | MAPTGAASYKTHRBTP53 | |
| SCHEMBL2291247 | 0.89 | MAPT (0.39) | MAPTGAASYKTHRBTP53 | |
| SCHEMBL2287284 | 0.85 | KCNN4 (0.39) | MAPTGAATHRBTP53TRPA1 | |
| SCHEMBL2289468 | 0.84 | TRPA1 (0.40) | MAPTGAAQPCTTP53TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032571-B1 | 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GMBH (DE) | 2014-12-03 | — | — | EP | claimed |
| US-8258151-B2 | 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors | MERCK PATENT GMBH (DE) | 2012-09-04 | — | — | US | claimed |
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2011-08-11 | — | — | US | claimed |
| EP-2032571-B1 | 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GMBH (DE) | 2014-12-03 | — | — | EP | disclosed |
| US-8258151-B2 | 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors | MERCK PATENT GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | GLP1R, SLC5A1, SLC5A2 | MAPT 1138/4885GAA 1202/4885SYK 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.